PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

Core Insights - PANTHERx Rare Pharmacy has been selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for the expanded indication of IMCIVREE (setmelanotide) for treating acquired hypothalamic obesity in adults and children aged 4 and older [1][2] Company Overview - PANTHERx Rare specializes in patient access and support services for personalized rare disease care, focusing on making complex therapies more accessible through individualized case management and comprehensive support [1][2] - Since its founding in 2011, PANTHERx has grown to become the largest independent rare pharmacy in the U.S., maintaining a balance between established resources and small-company responsiveness [2][3] Product and Indication Details - IMCIVREE is indicated for chronic weight management in patients aged 2 years and older with obesity due to specific genetic conditions, including Bardet-Biedl Syndrome and deficiencies in POMC, PCSK1, or LEPR [2] - Acquired hypothalamic obesity is characterized by accelerated weight gain due to hypothalamic injury, often resulting from tumors or other neurological conditions [4] Collaboration and Support - The partnership with Rhythm Pharmaceuticals aims to provide high-touch clinical support to patients navigating treatment for acquired hypothalamic obesity, which has historically had limited therapeutic options [2] - PANTHERx employs its proprietary RxARECARE model to enhance patient and caregiver support, ensuring a personalized approach to therapy management [1][2]